| scholarly article | Q13442814 |
| P50 | author | Lewis Kuller | Q88077314 |
| Diane G Ives | Q114401717 | ||
| P2093 | author name string | Fisher B | |
| Costantino JP | |||
| Dignam J | |||
| P2860 | cites work | Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer | Q28334666 |
| Tamoxifen, serum lipoproteins and cardiovascular risk | Q28361195 | ||
| Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee | Q35180289 | ||
| Long term effects of tamoxifen on blood lipid values in breast cancer | Q35822775 | ||
| Tamoxifen: teaching an old drug new tricks? | Q40968204 | ||
| A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors | Q41242105 | ||
| Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels | Q41415279 | ||
| Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group | Q42288190 | ||
| Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition | Q44541096 | ||
| Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. | Q51614708 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | tamoxifen | Q412178 |
| coronary artery disease | Q844935 | ||
| heart disease | Q190805 | ||
| P304 | page(s) | 776-782 | |
| P577 | publication date | 1997-06-01 | |
| P1433 | published in | Journal of the National Cancer Institute | Q400279 |
| P1476 | title | Coronary heart disease mortality and adjuvant tamoxifen therapy | |
| P478 | volume | 89 |
| Q35547296 | Agents that stabilise atherosclerotic plaque |
| Q33832651 | Antiestrogens--tamoxifen, SERMs and beyond |
| Q64118370 | Association between tamoxifen use and acute myocardial infarction in women with breast cancer |
| Q35194482 | Breast cancer chemoprevention: risk-benefit effects of the antioestrogen tamoxifen. |
| Q35767456 | Cardiovascular actions of selective estrogen receptor modulators and phytoestrogens |
| Q36595138 | Cardiovascular health and aromatase inhibitors |
| Q34585121 | Chemoprevention of breast cancer: implications for postmenopausal women |
| Q33688752 | Clinical pharmacology of selective estrogen receptor modulators |
| Q59288489 | Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial |
| Q28482848 | Development of a novel molecular sensor for imaging estrogen receptor-coactivator protein-protein interactions |
| Q37782092 | Early recurrence risk: aromatase inhibitors versus tamoxifen. |
| Q36115270 | Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Italian Chemoprevention Group |
| Q44604233 | Effect of tamoxifen at low doses on ultrasensitive C-reactive protein in healthy women. |
| Q46917690 | Effects of tamoxifen on myocardial ischemia-reperfusion injury model in ovariectomized rats |
| Q36383775 | Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women |
| Q43778268 | Endometrial lesions after tamoxifen therapy in breast cancer women |
| Q37435948 | Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen |
| Q35165822 | Favorable cardiac risk among elderly breast carcinoma survivors |
| Q33986414 | Heart disease in women |
| Q60357515 | Hormonal therapy of breast cancer |
| Q39396170 | Hormone Replacement Therapy for Primary and Secondary Prevention of Heart Disease |
| Q33843646 | Hormone replacement therapy and coronary heart disease. A new debate |
| Q43856978 | Hormone therapy and breast cancer: a review |
| Q36352053 | Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer |
| Q44241150 | Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats |
| Q34284548 | Manganese superoxide dismutase: beyond life and death |
| Q34742590 | Meta-analysis of vascular and neoplastic events associated with tamoxifen |
| Q50564769 | Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danis |
| Q34091195 | Orally administered endoxifen is a new therapeutic agent for breast cancer |
| Q77445325 | Osteoporosis in women: prevention and treatment |
| Q35934073 | Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations |
| Q38334309 | Plasma leptin concentration in tamoxifen-treated ovariectomized rats |
| Q35572427 | Prevention of breast cancer using SERMs and aromatase inhibitors |
| Q34030136 | Raloxifene: a review of its use in postmenopausal osteoporosis |
| Q57617595 | Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer |
| Q34326845 | Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer |
| Q44879129 | Selective estrogen receptor modulators: the ideal estrogen replacement?(2)(2). |
| Q35198543 | Selective estrogen-receptor modulators |
| Q73279544 | Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer |
| Q73544342 | Steroid regulation of tryptophan hydroxylase protein in the dorsal raphe of macaques |
| Q45265962 | Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina |
| Q53446252 | Tamoxifen: a personal retrospective. |
| Q41689704 | The Potential of SERMs for Reducing the Risk of Coronary Heart Disease |
Search more.